title: Quantitative and sensitive detection of GNAS mutations causing mccune-albright syndrome with next generation sequencing.
abstract: Somatic activating GNAS mutations cause McCune-Albright syndrome (MAS). Owing to low mutation abundance, mutant-specific enrichment procedures, such as the peptide nucleic acid (PNA) method, are required to detect mutations in peripheral blood. Next generation sequencing (NGS) can analyze millions of PCR amplicons independently, thus it is expected to detect low-abundance GNAS mutations quantitatively. In the present study, we aimed to develop an NGS-based method to detect low-abundance somatic GNAS mutations. PCR amplicons encompassing exons 8 and 9 of GNAS, in which most activating mutations occur, were sequenced on the MiSeq instrument. As expected, our NGS-based method could sequence the GNAS locus with very high read depth (approximately 100,000) and low error rate. A serial dilution study with use of cloned mutant and wildtype DNA samples showed a linear correlation between dilution and measured mutation abundance, indicating the reliability of quantification of the mutation. Using the serially diluted samples, the detection limits of three mutation detection methods (the PNA method, NGS, and combinatory use of PNA and NGS [PNA-NGS]) were determined. The lowest detectable mutation abundance was 1% for the PNA method, 0.03% for NGS and 0.01% for PNA-NGS. Finally, we analyzed 16 MAS patient-derived leukocytic DNA samples with the three methods, and compared the mutation detection rate of them. Mutation detection rate of the PNA method, NGS and PNA-NGS in 16 patient-derived peripheral blood samples were 56%, 63% and 75%, respectively. In conclusion, NGS can detect somatic activating GNAS mutations quantitatively and sensitively from peripheral blood samples. At present, the PNA-NGS method is likely the most sensitive method to detect low-abundance GNAS mutation.
authors.affiliation: Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan. sat_naru@hotmail.com
authors.forename: Satoshi
authors.initials: S
authors.lastname: Narumi
authors.forename: Kumihiro
authors.initials: K
authors.lastname: Matsuo
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Ishii
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Tanahashi
authors.forename: Tomonobu
authors.initials: T
authors.lastname: Hasegawa
mesh_terms: D002864:Chromogranins; D005260:Female; D005359:Fibrous Dysplasia, Polyostotic / Q000175:diagnosis* / Q000235:genetics*; D019205:GTP-Binding Protein alpha Subunits, Gs / Q000235:genetics*; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D008297:Male; D009154:Mutation; D059645:Mutation Rate; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: D002864:Chromogranins; C406732:GNAS protein, human; D019205:GTP-Binding Protein alpha Subunits, Gs
references.citation: J Pediatr. 2003 May;142(5):532-8
references.pmid: 12756386
references.citation: Bone. 1997 Aug;21(2):201-6
references.pmid: 9267696
references.citation: PLoS One. 2011;6(7):e22751
references.pmid: 21799941
references.citation: N Engl J Med. 1991 Dec 12;325(24):1688-95
references.pmid: 1944469
references.citation: N Engl J Med. 2011 Aug 18;365(7):611-9
references.pmid: 21793738
references.citation: Hum Pathol. 2012 Aug;43(8):1234-42
references.pmid: 22245114
references.citation: J Clin Endocrinol Metab. 2004 May;89(5):2107-13
references.pmid: 15126527
references.citation: Nat Genet. 2012 Jun 24;44(8):934-40
references.pmid: 22729224
references.citation: Nat Med. 2006 Jul;12(7):852-5
references.pmid: 16799556
references.citation: Nature. 2009 Sep 10;461(7261):272-6
references.pmid: 19684571
references.citation: Genome Biol. 2009;10(3):R25
references.pmid: 19261174
references.citation: J Bone Miner Res. 2000 Jan;15(1):120-8
references.pmid: 10646121
references.citation: Eur J Endocrinol. 2006 Dec;155(6):839-43
references.pmid: 17132753
references.citation: Bioinformatics. 2009 Aug 15;25(16):2078-9
references.pmid: 19505943